Cover Image
市場調查報告書

痘病毒感染:開發中產品分析

Poxvirus Infections - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 302491
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
痘病毒感染:開發中產品分析 Poxvirus Infections - Pipeline Review, H1 2016
出版日期: 2016年03月30日 內容資訊: 英文 39 Pages
簡介

痘病毒感染是因感染痘病毒而發病的一連串感染疾病。主要症狀有麻疹和高燒、發疹、肌肉痛、頭痛、身體疼痛、嘔吐等。主要治療法有抗病毒藥物等。

本報告提供全球各國治療痘病毒感染所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

痘病毒感染概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

痘病毒感染:企業開發中的治療藥

痘病毒感染:大學/機關研究中的治療藥

痘病毒感染:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

痘病毒感染:企業開發中的產品

痘病毒感染:大學/機關研究中的產品

痘病毒感染的治療藥的開發企業

  • China Biologic Products, Inc.
  • SIGA Technologies, Inc.
  • Symphogen A/S
  • 武田藥品工業

痘病毒感染:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 4-ThioIDU
  • Antibody for Poxvirus Infections
  • modified vaccinia ankara vaccine
  • Monoclonal Antibodies for Infectious Disease
  • Small Molecule to Inhibit DNA Synthesis for Poxvirus and Herpes Infections
  • Small Molecules to Inhibit Viral DNA Polymerase for Herpes and Poxvirus Infections
  • Sym-002
  • tecovirimat
  • varicella hyperimmune globulins

痘病毒感染:最近的開發平台趨勢

痘病毒感染:暫停中的計劃

痘病毒感染:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7780IDB

Summary

Global Markets Direct's, 'Poxvirus Infections - Pipeline Review, H1 2016', provides an overview of the Poxvirus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Poxvirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poxvirus Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Poxvirus Infections
  • The report reviews pipeline therapeutics for Poxvirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Poxvirus Infections therapeutics and enlists all their major and minor projects
  • The report assesses Poxvirus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Poxvirus Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Poxvirus Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Poxvirus Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Poxvirus Infections Overview
  • Therapeutics Development
    • Pipeline Products for Poxvirus Infections - Overview
    • Pipeline Products for Poxvirus Infections - Comparative Analysis
  • Poxvirus Infections - Therapeutics under Development by Companies
  • Poxvirus Infections - Therapeutics under Investigation by Universities/Institutes
  • Poxvirus Infections - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Poxvirus Infections - Products under Development by Companies
  • Poxvirus Infections - Products under Investigation by Universities/Institutes
  • Poxvirus Infections - Companies Involved in Therapeutics Development
    • China Biologic Products, Inc.
    • SIGA Technologies, Inc.
  • Poxvirus Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibody for Poxvirus Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Infectious Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DNA Synthesis for Poxvirus and Herpes Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tecovirimat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • varicella hyperimmune globulins - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Poxvirus Infections - Recent Pipeline Updates
  • Poxvirus Infections - Dormant Projects
  • Poxvirus Infections - Product Development Milestones
    • Featured News & Press Releases
      • Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral
      • Mar 12, 2013: Siga Delivers First Courses Of Arestvyr To US Strategic National Stockpile Under BARDA Contract
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Poxvirus Infections, H1 2016
  • Number of Products under Development for Poxvirus Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Poxvirus Infections - Pipeline by China Biologic Products, Inc., H1 2016
  • Poxvirus Infections - Pipeline by SIGA Technologies, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Poxvirus Infections Therapeutics - Recent Pipeline Updates, H1 2016
  • Poxvirus Infections - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Poxvirus Infections, H1 2016
  • Number of Products under Development for Poxvirus Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top